A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
An expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Transferability of cephalothin to the alveolar cavity in thoroughbreds. (1/26)

Five Thoroughbreds were classified into 4 groups according to the administration method used for saline solution (saline), ambroxol, and cephalothin sodium (cephalothin). In group A, cephalothin was injected intravenously after oral administration of ambroxol. In group B, cephalothin was injected intravenously after oral administration of saline. Groups C and D were used as control groups. The dose of cephalothin or ambroxol was clinically administrated. Venous blood and bronchoalveolar lavage fluid (BALF) were sampled from each group. In groups A and B, cephalothin concentrations in plasma reached their maximum level 5 min after cephalothin administration and then declined over time. In plasma obtained from groups A and B, there were no significant differences in pharmacokinetic parameters (T1/2, Kel, Vd). By contrast, cephalothin concentrations in BALF reached their peak at 180 min after cephalothin administration in both groups A and B and maintained a relatively high level even after 300 min. These findings indicate that cephalothin requires a relatively long period of time to move from the blood stream to the alveolar cavity, but once transferred to the alveolar cavity, it is preserved for a long time. In groups A and B, cephalothin concentrations in BALF were approximately at the same level. However, in group A, total protein in BALF was lower at 60, 180, and 300 min than the other groups. Then, cephalothin concentration was adjusted to total protein in BALF. After adjustment to total protein in BALF, group A showed a concentration level of cephalothin approximately 1.5-fold higher than that of group B. This suggests that the transferability of cephalothin to the alveolar cavity improves as a result of the oral administration of ambroxol.  (+info)

Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia (BPD). (2/26)

In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia]. The aim of the present analysis was to investigate the effect of Ambroxol treatment on lung function in newborns who developed BPD. Respiratory function testing (RFT) was performed immediately after extubation and at day 28. Tidal volume (VT) and respiratory frequency (f) were measured during tidal breathing using the deadspace free flow-through technique. The lung mechanic parameter VT/maxPes was determined by measuring the maximal oesophageal pressure changes, maxPes, with a catheter tip pressure transducer. In the placebo group 36/50 infants were extubated within the first 28 days of life and 13/36 (36%) developed BPD. In the Ambroxol group 44/52 were extubated and 9/44 (20%) developed BPD. After extubation, RFT showed (i) no statistically significant difference in the ventilatory parameters of either treatment group, (ii) improved (P<0.05) lung mechanics (VT/maxPes) in Ambroxol group compared to controls (94+/-27 ml kPa(-1) vs. 8.1+/-2.6 ml kPa(-1)) and (iii) no statistically significant difference in lung function between infants with and without BPD. At day 28 we found (i) no effect of early Ambroxol treatment on lung functions, (ii) significantly (P < 0.05) higher f (58.5+/-11.7 min(-1) vs. 49.7+/-10.1 min(-1)) and significantly (P<0.01) lower V(T) (9.6+/-1.9 ml vs. 12.3+/-2.7 ml) and V(T)/maxPes (8.9+/-2.6 ml kPa(-1)] vs. 12.0+/-2.9 ml kPa(-1)) in infants with BPD compared to infants without and (iii) these differences are not influenced by early Ambroxol treatment. If the process of BPD development is induced, early Ambroxol treatment has no influence on impaired lung function at day 28.  (+info)

Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages. (3/26)

BACKGROUND: N-acetylcysteine (NAC) and ambroxol (AMB) have recently been proposed as possible therapeutic agents in the treatment of pulmonary disorders. IL-12 plays an important role in host resistance to infection and the development of Th-1 cells. In contrast, IL-10 is involved in anti-inflammatory and immunoregulatory mechanisms. OBJECTIVE: We investigated the effects of NAC and AMB on secretions of IL-12 and IL-10 from human alveolar macrophages. METHODS: Alveolar macrophages were obtained from 7 healthy nonsmokers by bronchoalveolar lavage. The cells were first incubated with either NAC or AMB for 2 h and then cultured in lipopolysaccharide (LPS) solution for 24 h. IL-12 and IL-10 secretions were measured by ELISA. RESULT: Both NAC and AMB enhanced LPS-induced secretion of IL-12. NAC also enhanced LPS-induced IL-10 secretion, while AMB did not. The ratio IL-12/IL-10 secretion was increased by AMB, but NAC did not affect it. CONCLUSIONS: The results suggest that NAC enhances inflammatory and immune responses and prevents excessive responses reciprocally, through keeping local balance of IL-12 and IL-10 production in alveolar macrophages at inflammatory sites of bacterial pneumonia. AMB appears to strengthen inflammatory responses and cell-mediated immunity, facilitating the development of Th-1 cells, through shifting the local balance to IL-12 dominance.  (+info)

Depressant effect of ambroxol on stimulated functional responses and cell death in rat alveolar macrophages exposed to silica in vitro. (4/26)

The present study examined the effect of ambroxol on free radical production, granule enzyme release, and cell death in silica-activated rat alveolar macrophages. The action of ambroxol was assayed by measuring changes in the activities of protein kinase C (PKC) and tyrosine kinase (PTK) and in the intracellular calcium level. Ambroxol attenuated the production of superoxide, hydrogen peroxide, and nitric oxide and the release of acid phosphatase and lysozyme in macrophages activated by silica. Staurosporine, genistein, EGTA, and trifluoperazine inhibited the silica-induced free radical production and granule enzyme release. Silica induced the increase in PKC and PTK activities and the elevation of intracellular calcium level in macrophages, which was decreased by ambroxol. Silica induced a cell death and increased the caspase-3 activity in macrophages in a concentration-dependent manner. Ambroxol decreased the silica-induced cell viability loss in macrophages. The results show that ambroxol decreases the stimulated responses and cell death in rat alveolar macrophages exposed to silica, which may be accomplished by inhibition of activation processes, protein kinases, and calcium transport. The inhibitory effect of ambroxol on silica-induced cell death appears to provide the protective effect on pulmonary tissues against the toxic action of silica.  (+info)

Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. (5/26)

The protective effect of ambroxol, a mucolytic agent which has antioxidant properties and stimulates the release of pulmonary surfactant, against influenza-virus proliferation in the airway was investigated in mice. Ambroxol or the vehicle was administered intraperitoneally twice a day for 5-7 days to mice shortly after intranasal infection with a lethal dose of influenza A/Aichi/68 (H3N2) virus, and the survival rate, virus titre and levels of factors regulating virus proliferation in the airway fluid were analysed. Ambroxol significantly suppressed virus multiplication and improved the survival rate of mice. The effect of ambroxol reached a peak at 10 mg x kg(-1) x day(-1), higher doses being less effective. Ambroxol stimulated the release of suppressors of influenza-virus multiplication, such as pulmonary surfactant, mucus protease inhibitor, immunoglobulin (Ig)-A and IgG, although it stimulated the release of a trypsin-type protease that potentiates virus proliferation. In addition, ambroxol transiently suppressed release of the cytokines, tumour necrosis factor-alpha, interferon-gamma and interleukin-12, into airway fluid. Although ambroxol had several negative effects on the host defence system, overall it strikingly increased the concentrations of suppressors of influenza-virus multiplication in the airway.  (+info)

Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol. (6/26)

Ambroxol has a long history for the treatment of airway diseases because of its beneficial effects on surfactant synthesis and mucus-modifying properties. Some findings, however, point to an additional effect on neuronal signal transduction: ambroxol can suppress reflexes such as the cough or the corneal reflex. The airways and the cornea are innervated by C-fibers, which express voltage-gated Na(+) channels with and without sensitivity to tetrodotoxin (TTX). In this study, we performed voltage-clamp experiments to investigate whether ambroxol affects these channel types. In rat dorsal root ganglia, TTX-resistant Na(+) currents were suppressed in a concentration-dependent manner with IC(50) values of 35.2 and 22.5 microM for tonic and phasic block, respectively. Depolarizing prepulses increased the potency of ambroxol, and steady-state inhibition curves were shifted to more negative values. The inhibition was not frequency-dependent. TTX-sensitive currents were inhibited with lower potency (approximately 50% inhibition with 100 microM). Recombinant rat brain IIA channels in Chinese hamster ovary cells were blocked with IC(50) values of 111.5 and 57.6 microM for tonic and phasic block, respectively; in contrast to TTX-resistant channels the block was frequency-dependent. Thus, ambroxol indeed blocks neuronal voltage-gated Na(+) channels, and TTX-resistant channels in sensory neurons were more sensitive than TTX-sensitive. Compared with known local anesthetics (e.g., lidocaine or benzocaine), the potency for Na(+) channel block was relatively high. A recent clinical trial has further confirmed that ambroxol relieved pain and was beneficial in patients who suffered from sore throat.  (+info)

Pulmonary alveolar proteinosis successfully treated with ambroxol. (7/26)

A 79-year-old woman was admitted to hospital due to a four-month history of a cough and dyspnea on exertion. Chest CT scans revealed ground glass opacity with thickened interlobular septa in both lungs. Bronchoalveolar lavage fluid (BALF) had milky appearance and revealed large acellular eosinophilic amorphous bodies positively stained with periodic acid-Schiff (PAS). Autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) were present in sera and BALF from the patient. Ambroxol was started in a daily dose of 45 mg orally. Her oxygen saturation improved and abnormal shadows in CT scan disappeared 6 months after beginning the therapy.  (+info)

In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism. (8/26)

Neutrophils are major culprits for the protease/antiprotease imbalance during various lung diseases, that is, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis and adult respiratory distress syndrome. Thus, these cells are presently considered an ideal target for the pharmacologic control of tissue injury during these diseases. This study was planned in order to investigate if ambroxol and its precursor bromhexine are actually capable of preventing alpha-1-antitrypsin (A1AT) inactivation by stimulated neutrophils and possibly to look into the mechanisms underlying this event. Ambroxol inhibited the production of superoxide anion by activated neutrophils, whereas bromhexine had no inhibitory effect. Ambroxol decreased the production of hypochlorous acid (HOCl) from activated neutrophils with high efficiency, whereas bromhexine had a modest activity. Ambroxol and bromhexine were capable of limiting the chlorination of monochlorodimedon by HOCl, displaying the capacity of directly scavenging the oxidant. Ambroxol decreased the release of elastase and myeloperoxidase from activated neutrophils, whereas bromhexine was ineffective. Ambroxol prevented the A1AT inactivation by neutrophils, whereas bromhexine was completely ineffective. Among drugs currently available for in vivo use in humans, ambroxol is unique by virtue of its ability to prevent neutrophil-mediated A1AT inactivation via inhibition of HOCl production as well as HOCl scavenging. Also taking into account its capacity for curbing elastase release, the drug displays the potential to lessen the burden of oxidants/proteases and to increase the antiprotease shield at the site of inflammation. Thus, ambroxol appears to be a good candidate for raising attempts to develop new therapeutic histoprotective approaches to inflammatory bronchopulmonary diseases.  (+info)

Both ambroxol and its parent drug bromhexine have been shown to induce autophagy in several cell types, and ambroxol was shown ... Ambroxol is also anti-inflammatory, reducing redness in a sore throat. Ambroxol has recently been shown to increase activity of ... Ambroxol is often administered as an active ingredient in cough syrup. It was patented in 1966 and came into medical use in ... Ambroxol also provides pain relief in acute sore throat. Pain in sore throat is the hallmark of acute pharyngitis. Sore throat ...
Examples are carbocisteine, ambroxol, and bromhexine. Expectorants are substances claimed to make coughing easier while ... ambroxol, and guaifenesin, sometimes with analgesics, antipyretics, anti inflammatories, and anticholinergics; and for children ...
Ambroxol is a drug that reduces mucus. Preclinical research suggests it may produce analgesic effects by blocking sodium ... Russo, Marc A.; Baron, Ralf; Dickenson, Anthony H.; Kern, Kai-Uwe; Santarelli, Danielle M. (17 May 2022). "Ambroxol for ...
Choi SW, Gu Y, Peters RS, Salgame P, Ellner JJ, Timmins GS, Deretic V (July 2018). "Ambroxol induces autophagy and potentiates ... and ambroxol (through host directed effects in autophagy and pharmacokinetics). Rifampicin inhibits bacterial DNA-dependent RNA ...
Ambroxol is a lysosomotropic drug of clinical use to treat conditions of productive cough for its mucolytic action. Ambroxol ... Presumably for this reason, Ambroxol was also found to improve cellular function in some disease of lysosomal origin such as ... Ambroxol triggers lysosomal exocytosis via pH-dependent Ca²⁺ release from acidic Ca²⁺ stores". Cell Calcium. 58 (6): 628-37. ... "Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells". Brain. 137 (Pt 5): ...
Ambroxol has recently been shown to increase activity of the lysosomal enzyme glucocerebrosidase, so it may be a useful ... Ambroxol triggers the secretion of lysosomes from cells by inducing a pH-dependent calcium release from acidic calcium stores. ... Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores". Cell Calcium. 58 (6): 628-637. ... "Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells". Brain. 137 (5): 1481- ...
LCT has supported trials in ambroxol, exenatide, simvastatin, liraglutide, and others. In October, the institute announced a ...
Ambroxol is another drug that has beneficial effects in Vero E6 cells. A comprehensive review with over 1,500 citations by ... "Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations". bioRxiv ...
2008). "Upregulation of AQP3 and AQP5 induced by dexamethasone and ambroxol in A549 cells". Respiratory Physiology & ...
cefuroxime and ambroxol". Arzneimittel-Forschung. 50 (8): 700-11. doi:10.1055/s-0031-1300276. PMID 10994153. "ELOM-080: Was ... cefuroxime and ambroxol". Arzneimittel-Forschung. Editio Cantor Verlag. 50 (8): 700-11. doi:10.1055/s-0031-1300276. PMID ...
In contrast to Bay K8644, which is not for clinical use, ambroxol is a frequently used mucolytic drug that triggers lysosomal ... Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores". Cell Calcium. 58 (6): 628-637. ...
... sobrerol and ambroxol). Chronic Obstructive Pulmonary Disease Evidence obtained in patients with stable chronic bronchitis/COPD ...
... ambroxol, salbutamol, phenylephrine, and dexamethasone. The marketing of the Claritin brand is important in the history of ...
Therapies under study as of 2019 aim to reduce brain levels of alpha-synuclein (with the pharmaceuticals ambroxol, NPT200-11, ...
... ambroxol, bromhexine, carbocisteine, erdosteine, mecysteine, and dornase alfa. Balsamo, R.; Lanata, L.; Egan, C. G. (2010). " ...
... ambroxol MeSH D02.092.146.290 - benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide MeSH ... ambroxol MeSH D02.092.471.200 - cystamine MeSH D02.092.471.245 - dibenzylchlorethamine MeSH D02.092.471.302 - diethylamines ...
Cineole R05CB01 Acetylcysteine R05CB02 Bromhexine R05CB03 Carbocisteine R05CB04 Eprazinone R05CB05 Mesna R05CB06 Ambroxol ...
... ambroxol) Pharmaton (standardized ginseng extract, vitamins, minerals, trace elements) Silomat / Bisoltussin / Bisolvon ...
... ambroxol (INN) ambruticin (INN) ambucaine (INN) ambucetamide (INN) ambuside (INN) Amcill amcinafal (INN) amcinafide (INN) ...
... combinations R03CC63 Clenbuterol and ambroxol QR03CC90 Clenbuterol, combinations R03DA01 Diprophylline R03DA02 Choline ...
Syrup; Oral; Ambroxol 15 mg / 5 ml*Tablets; Oral; Ambroxol 30 mg. ...
Showing the single result. ...
Ambroxol chlohydrate. API. N° CAS 23828-92-4. Drugs for obstructive airway diseases. *Ambroxol hydrochloride is a brominated ...
Ambroxol Injection 30 mg/100ml China, if you want to buy China Ambroxole Injection 30mg/100ml, please contact us. ... We are manufacturer of Ambroxol Injection 30 mg/100ml, ... Ambroxol is a clinically proven systemically active mucolytic ... Ambroxol Indications. All forms of tracheobronchitis, emphysema with bronchitis pneumoconiosis, chronic inflammatory pulmonary ... Location: Home ,Finished Drugs ,Respiratory & Digestive System Drug , Ambroxol Injection 30 mg/100ml ...
The company also offers Ambroxol & Levocetirizine Tablets PCD Pharma Franchise. ... Contact the best Ambroxol & Levocetirizine Tablets manufacturer and supplier, this medicine comes with the branding of ... Ambroxol on the other hand is an expectorant that promotes the secretion of phlegm and it is also a mucolytic agent that makes ... Ambroxol & Levocetirizine Tablets may cause some side effects which arent major in nature as they tend to go away with time as ...
Ambroxol; Nascimento Prematuro; Síndrome do Desconforto Respiratório do Recém-Nascido; Recém-Nascido; Lactente; Feminino; ... Therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride on respirat Therapeutic effect of micropump ... This work aimed to explore the therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride (AH) on ... Ambroxol Tipo de estudo: Ensaio clínico controlado Limite: Criança / Feminino / Humanos / Lactente / Recém-Nascido Idioma: ...
Ambroxol 15mg+Guaifenesin 50mg+Terbutaline 1.5mg+Menthol 2.5 mg, BRAND NAME: ABITUSS-A, PACKING: 100ml, MRP: 58 ... COMPOSITION: Ambroxol 15mg+Guaifenesin 50mg+Terbutaline 1.5mg+Menthol 2.5 mg. PACKING: 100ml. MRP: 58 ... Ambroxol 15mg+Guaifenesin 50mg+Terbutaline 1.5mg+Menthol 2.5 mg Syrup. ₹58.00. ...
Topical administration of ambroxol eye drops augments tear secretion in rabbits. 29 January 2021 ...
Ambroxol 30 Mg Ambroxol+Levosalbutamol+Guaifenesin is used in the treatment of cough with mucus. ... Question: What is Ambroxol+Levosalbutamol+Guaifenesin?. Answer: Ambroxol+Levosalbutamol+Guaifenesin is a combination of three ... Question: Is it safe to use Ambroxol+Levosalbutamol+Guaifenesin?. Answer: Yes, it is safe to use Ambroxol+Levosalbutamol+ ... Ambroxol + Levosalbutamol + Guaifenesin is a combination of three medicines: Ambroxol , Levosalbutamol and Guaifenesin, which ...
Ambroxol HCl 15 mg. Children aged 2-5 yrs: 5 mL. Children aged 1-2 yrs: 2.5 mL ...
Ambroxol (15mg) + Guaifenesin (50mg) + Phenylephrine (5mg), by Aventura Healthcare Pvt Ltd for Common cold symptoms,Cough, ... Salt- Levocetirizine (1mg) + Ambroxol (15mg) + Guaifenesin (50mg) + Phenylephrine (5mg),. Manufacturer- Aventura Healthcare Pvt ...
Ambroxol 543. View Price View Price 123. Ambroxol (SR). 10. - View Price ...
Supplier of Cetirizine Phenylephrine HCL Ambroxol HCL and Paracetamol Tablets based in Khandwa, India ... Cetirizine Phenylephrine HCL Ambroxol HCL and Paracetamol Tablets. *Diciofenac Potassium Paracetamol and Sematiopeptidase ... Get a price quote for Cetirizine Phenylephrine HCL Ambroxol HCL and Paracetamol Tablets ...
Ambroxol ( Safe. Compatible. Minimal risk for breastfeeding and infant.). *Bromhexine ( Safe. Compatible. Minimal risk for ...
Strepsils (ambroxol) chesty cough lozenge P GSL 2018/03/01. Maxigesic (paracetamol/ibuprofen) 500/150mg tablet. POM GSL 2018/02 ... Mucosolvan (ambroxol) 24 hours capsule 75mg, tablet 30mg and liquid 30mg/5ml. P. GSL. 2018/07/23. ...
Dysprosium particles decorated Ambroxol imprinted polymer sensor to detect carbide-treated mango ...
Researchers report ambroxol increases the level of GCase, a protein that allows cells to remove waste proteins including alpha ... Ambroxol, a common medicine used to treat respiratory illnesses shows promise as a treatment to slow the progression of ... Once the ambroxol trial is underway, it will be one of only six Phase 3 trials on public record of potentially disease- ... Summary: Ambroxol, a common medicine used to treat respiratory illnesses shows promise as a treatment to slow the progression ...
Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998;92:609-23. ... A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur ...
Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Free. Radic. Biol. Med., 19: 659-663.. PubMed ... ambroxol (Nowak et al., 1995) were tried with limited success. In the line, Probucol, a lipid lowering agent was found to offer ...
Four days after symptom onset, he went to a private clinic and began treatment with amoxicillin and ambroxol but did not ...
Ambroxol Dr.Max 15 mg/5 ml sirup 1x100 ml, sirup 5,59 € ...
All contain ambroxol. Commercialization of Lysopaïne® and Lizipadol® brands is limited to certain countries. ... Both formulations are sold under three different brand names worldwide: Mucoangin®, Lysopaïne® Ambroxol, and Lizipadol®. ... Mucoangin® contains ambroxol, an efficacious and well-tolerated local anesthetic which relieves sore throat pain by blocking ... Beside its local anesthetic effect, ambroxol also has anti-inflammatory properties. This anti-inflammatory effect has been ...
Ambroxol. 06/09/2022. Esketamine. 01/09/2022. Melphalan captisol. 01/09/2022. ...
Ambroxol. 06/09/2022. Esketamine. 01/09/2022. Melphalan captisol. 01/09/2022. ...
Ambroxol belongs to the class of mucolytic agents (cough/sputum thinner) that work by thinning and loosening phlegm (mucus) in ... Ambroxol belongs to the class of mucolytic agents (cough/sputum thinner) that work by thinning and loosening phlegm (mucus) in ... Ambroxol is a mucolytic agent (cough/sputum thinner) that works by thinning and loosening phlegm (mucus) in lungs, windpipe and ... Kofirax Syrup 100 ml is a combination of three drugs, namely: Levosalbutamol, Ambroxol, and Guaifenesin used to treat cough ...
ambroxol. Liečivo je dostupné vo forme tabliet a sirupu. Zriedi bronchiálny pľúcny hlien a zabraňuje jeho tvorbe v pľúcach. ... Deti od 2 do 5 rokov majú podávať ambroxol vo forme sirupu 2,5 ml trikrát denne. Pacienti vo veku od 5 rokov dávkovanie zvyšujú ... Ambroxol. Je predpísaný na výskyt kašľa s ťažkým vylučovaním hlienu. Podporuje rednutie a vykašliavanie spúta. ... Zvýšenie produktivity kašľa, Ambroxol vyčistí priedušky zo spúta a obnoví ich čistiacu funkciu. ...
Effect of ambroxol on whole lung mucociliary clearance in sheep.. Source: International Congress 2017 - Towards better ... Comparison with N-acetylcysteine and ambroxol. Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and ...
Ambroxol HCl. B2267-50 ApexBio 50 mg. 129.6 EUR Description: AmbroxolHCl is a potent inhibitor of the neuronal Na+ channels, ...
  • Ambroxol+Levosalbutamol+Guaifenesin is used in the treatment of cough with mucus. (mkhealthcare.co.in)
  • Ambroxol + Levosalbutamol + Guaifenesin is a combination of three medicines: Ambroxol , Levosalbutamol and Guaifenesin, which relieves cough with mucus. (mkhealthcare.co.in)
  • Question: What is Ambroxol+Levosalbutamol+Guaifenesin? (mkhealthcare.co.in)
  • Answer: Ambroxol+Levosalbutamol+Guaifenesin is a combination of three medicines: Ambroxol, Levosalbutamol / Levalbuterol, Guaifenesin. (mkhealthcare.co.in)
  • Question: Is it safe to use Ambroxol+Levosalbutamol+Guaifenesin? (mkhealthcare.co.in)
  • Answer: Yes, it is safe to use Ambroxol+Levosalbutamol+Guaifenesin in most of the patients. (mkhealthcare.co.in)
  • Question: Are there any specific contraindications associated with the use of Ambroxol+Levosalbutamol+Guaifenesin? (mkhealthcare.co.in)
  • Answer: Use of Ambroxol+Levosalbutamol+Guaifenesin is considered to be harmful in patients with a history of allergy to any of the active or inactive ingredients. (mkhealthcare.co.in)
  • Question: Can the use of Ambroxol+Levosalbutamol+Guaifenesin cause dizziness? (mkhealthcare.co.in)
  • Answer: Yes, the use of Ambroxol+Levosalbutamol+Guaifenesin can cause dizziness (feeling faint, weak, unsteady or lightheaded) in some patients. (mkhealthcare.co.in)
  • Question: Can the use of Ambroxol+Levosalbutamol+Guaifenesin cause diarrhea? (mkhealthcare.co.in)
  • What are the recommended storage conditions for Ambroxol+Levosalbutamol+Guaifenesin? (mkhealthcare.co.in)
  • Kofirax Syrup 100 ml is a combination of three drugs, namely Levosalbutamol (bronchodilator), Ambroxol (mucolytic agent), and Guaifenesin (expectorant). (apollopharmacy.in)
  • Kofirax Syrup 100 ml is a combination of three drugs, namely: Levosalbutamol, Ambroxol, and Guaifenesin used to treat cough associated with mucus. (apollopharmacy.in)
  • Ambroxol hydrochloride is a brominated chemical of the cyclohexanol family. (unipex.com)
  • Therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride on respiratory distress syndrome in premature infants. (bvsalud.org)
  • This work aimed to explore the therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride (AH) on respiratory distress syndrome (RDS) in premature infants . (bvsalud.org)
  • HISTACOVE-AX is the combination of Ambroxol & Levocetirizine Tablets which is used to treat various respiratory tract disorders that are linked with viscid mucus. (jabsbiotech.com)
  • Ambroxol & Levocetirizine Tablets may cause some side effects which aren't major in nature as they tend to go away with time as the body starts to adjust itself with time. (jabsbiotech.com)
  • The firm is acknowledged as the best Ambroxol & Levocetirizine Tablets manufacturer and supplier in India. (jabsbiotech.com)
  • To cater the different needs of the people we are also offering Ambroxol & Levocetirizine Tablets PCD Pharma Franchise with compete monopoly rights. (jabsbiotech.com)
  • Ambroxol is a clinically proven systemically active mucolytic agent. (apharma-voice.com)
  • Ambroxol on the other hand is an expectorant that promotes the secretion of phlegm and it is also a mucolytic agent that makes the sputum less viscous and then it makes breathing easier for the individual. (jabsbiotech.com)
  • Ambroxol is a mucolytic which thins and loosens mucus (phlegm), making it easier to cough out. (mkhealthcare.co.in)
  • Ambroxol is a mucolytic. (mkhealthcare.co.in)
  • Ambroxol belongs to the class of mucolytic agents (cough/sputum thinner) that work by thinning and loosening phlegm (mucus) in the lungs, windpipe, and nose. (apollopharmacy.in)
  • Ambroxol, a common medicine used to treat respiratory illnesses shows promise as a treatment to slow the progression of Parkinson's disease. (neurosciencenews.com)
  • Ambroxol is a drug which is currently used to treat respiratory conditions. (neurosciencenews.com)
  • Mucoangin ® contains ambroxol, an efficacious and well-tolerated local anesthetic which relieves sore throat pain by blocking the pain receptors in the throat. (boehringer-ingelheim.cz)
  • Researchers report ambroxol increases the level of GCase, a protein that allows cells to remove waste proteins including alpha-synuclein. (neurosciencenews.com)
  • Once the ambroxol trial is underway, it will be one of only six Phase 3 trials on public record of potentially disease-modifying drugs in Parkinson's, worldwide. (neurosciencenews.com)
  • Four days after symptom onset, he went to a private clinic and began treatment with amoxicillin and ambroxol but did not recover. (cdc.gov)
  • After the Phase 2 data from Professor Schapira's group at UCL found that ambroxol could increase the removal of alpha-synuclein, the international Linked Clinical Trials (iLCT) program prioritized research into the drug. (neurosciencenews.com)
  • Results of the Phase 2 clinical trial by Professor Schapira and performed at UCL was published in January 2020 and tested ambroxol in people with Parkinson's. (neurosciencenews.com)